BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nordström AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-35. [PMID: 8097114 DOI: 10.1016/0006-3223(93)90288-o] [Cited by in Crossref: 340] [Cited by in F6Publishing: 70] [Article Influence: 12.1] [Reference Citation Analysis]
Number Citing Articles
1 Miller R. Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I. Curr Neuropharmacol 2009;7:302-14. [PMID: 20514210 DOI: 10.2174/157015909790031229] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
2 Liu-Seifert H, Kinon BJ, Tennant CJ, Sniadecki J, Volavka J. Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatr Dis Treat 2009;5:47-54. [PMID: 19557099 DOI: 10.2147/ndt.s4766] [Cited by in Crossref: 27] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
3 McCormick PN, Kapur S, Graff-Guerrero A, Raymond R, Nobrega JN, Wilson AA. The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro. Neuropsychopharmacology 2010;35:1826-35. [PMID: 20410873 DOI: 10.1038/npp.2010.50] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 4.7] [Reference Citation Analysis]
4 Suzuki K, Kimura H. TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia. CNS Neurosci Ther 2018;24:604-14. [PMID: 29318783 DOI: 10.1111/cns.12798] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
5 Girgis RR, Forbes A, Abi-Dargham A, Slifstein M. A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia. Neuropsychopharmacology 2020;45:786-92. [PMID: 31847007 DOI: 10.1038/s41386-019-0590-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
6 Lyon GJ, Abi-Dargham A, Moore H, Lieberman JA, Javitch JA, Sulzer D. Presynaptic regulation of dopamine transmission in schizophrenia. Schizophr Bull 2011;37:108-17. [PMID: 19525353 DOI: 10.1093/schbul/sbp010] [Cited by in F6Publishing: 36] [Reference Citation Analysis]
7 Li P, Snyder GL, Vanover KE. Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future. Curr Top Med Chem 2016;16:3385-403. [PMID: 27291902 DOI: 10.2174/1568026616666160608084834] [Cited by in Crossref: 106] [Cited by in F6Publishing: 51] [Article Influence: 26.5] [Reference Citation Analysis]
8 Bonoldi I, Howes OD. Presynaptic dopaminergic function: implications for understanding treatment response in psychosis. CNS Drugs 2014;28:649-63. [PMID: 24919790 DOI: 10.1007/s40263-014-0177-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
9 Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des 2009;15:2550-9. [PMID: 19689327 DOI: 10.2174/138161209788957528] [Cited by in Crossref: 157] [Cited by in F6Publishing: 128] [Article Influence: 13.1] [Reference Citation Analysis]
10 Muly EC, Votaw JR, Ritchie J, Howell LL. Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone. J Pharmacol Exp Ther 2012;341:81-9. [PMID: 22214649 DOI: 10.1124/jpet.111.189076] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
11 Pilowsky LS, Busatto GF, Taylor M, Costa DC, Sharma T, Sigmundsson T, Ell PJ, Nohria V, Kerwin RW. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl) 1996;124:148-53. [PMID: 8935810 DOI: 10.1007/BF02245615] [Cited by in Crossref: 67] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
12 Barrie ES, Smith RM, Sanford JC, Sadee W. mRNA transcript diversity creates new opportunities for pharmacological intervention. Mol Pharmacol 2012;81:620-30. [PMID: 22319206 DOI: 10.1124/mol.111.076604] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
13 Varnäs K, Varrone A, Farde L. Modeling of PET data in CNS drug discovery and development. J Pharmacokinet Pharmacodyn 2013;40:267-79. [PMID: 23660778 DOI: 10.1007/s10928-013-9320-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
14 Kapur S, Agid O, Mizrahi R, Li M. How antipsychotics work-from receptors to reality. NeuroRx 2006;3:10-21. [PMID: 16490410 DOI: 10.1016/j.nurx.2005.12.003] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
15 Geerts H, Spiros A, Roberts P, Twyman R, Alphs L, Grace AA. Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response. PLoS One 2012;7:e49732. [PMID: 23251349 DOI: 10.1371/journal.pone.0049732] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
16 Ulrich S, Wurthmann C, Brosz M, Meyer FP. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet 1998;34:227-63. [PMID: 9533984 DOI: 10.2165/00003088-199834030-00005] [Cited by in Crossref: 60] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
17 Wong DF, Raoufinia A, Bricmont P, Brašić JR, McQuade RD, Forbes RA, Kikuchi T, Kuwabara H. An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants. Eur J Clin Pharmacol 2021;77:717-25. [PMID: 33196868 DOI: 10.1007/s00228-020-03021-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A, Russu A. Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data. CNS Drugs 2017;31:273-88. [PMID: 28258365 DOI: 10.1007/s40263-017-0416-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
19 Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K, Bear MF, Umbricht D, Hajos M, Potter WZ, Lee CM. Translating glutamate: from pathophysiology to treatment. Sci Transl Med 2011;3:102mr2. [PMID: 21957170 DOI: 10.1126/scitranslmed.3002804] [Cited by in Crossref: 109] [Cited by in F6Publishing: 99] [Article Influence: 12.1] [Reference Citation Analysis]
20 Khan ZU, Mrzljak L, Gutierrez A, de la Calle A, Goldman-Rakic PS. Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci U S A 1998;95:7731-6. [PMID: 9636219 DOI: 10.1073/pnas.95.13.7731] [Cited by in Crossref: 184] [Cited by in F6Publishing: 165] [Article Influence: 8.0] [Reference Citation Analysis]
21 Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015;29:97-115. [PMID: 25586400 DOI: 10.1177/0269881114563634] [Cited by in Crossref: 380] [Cited by in F6Publishing: 272] [Article Influence: 63.3] [Reference Citation Analysis]
22 Musco S, McAllister V, Caudle I. Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment. Ther Adv Psychopharmacol 2020;10:2045125320937575. [PMID: 32922732 DOI: 10.1177/2045125320937575] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
23 Bressan RA, Erlandsson K, Spencer EP, Ell PJ, Pilowsky LS. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology (Berl) 2004;175:367-73. [PMID: 14997280 DOI: 10.1007/s00213-004-1826-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
24 Vanover KE, Davis RE, Zhou Y, Ye W, Brašić JR, Gapasin L, Saillard J, Weingart M, Litman RE, Mates S, Wong DF. Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia. Neuropsychopharmacology 2019;44:598-605. [PMID: 30449883 DOI: 10.1038/s41386-018-0251-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 7.7] [Reference Citation Analysis]
25 Girault EM, Alkemade A, Foppen E, Ackermans MT, Fliers E, Kalsbeek A. Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance. PLoS One 2012;7:e43244. [PMID: 22905238 DOI: 10.1371/journal.pone.0043244] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
26 Smith CT, Dang LC, Buckholtz JW, Tetreault AM, Cowan RL, Kessler RM, Zald DH. The impact of common dopamine D2 receptor gene polymorphisms on D2/3 receptor availability: C957T as a key determinant in putamen and ventral striatum. Transl Psychiatry 2017;7:e1091. [PMID: 28398340 DOI: 10.1038/tp.2017.45] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
27 Sim K, Su HC, Fujii S, Yang SY, Chong MY, Ungvari G, Si T, He YL, Chung EK, Chan YH, Shinfuku N, Kua EH, Tan CH, Sartorius N. High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. Br J Clin Pharmacol 2009;67:110-7. [PMID: 19133060 DOI: 10.1111/j.1365-2125.2008.03304.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
28 Arakawa R, Takano A, Halldin C. PET technology for drug development in psychiatry. Neuropsychopharmacol Rep 2020;40:114-21. [PMID: 32463584 DOI: 10.1002/npr2.12084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
29 Nord M, Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther. 2011;17:97-103. [PMID: 21143431 DOI: 10.1111/j.1755-5949.2010.00222.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 70] [Article Influence: 8.9] [Reference Citation Analysis]
30 Coccurello R, Caprioli A, Ghirardi O, Conti R, Ciani B, Daniele S, Bartolomucci A, Moles A. Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. Psychopharmacology (Berl) 2006;186:561-71. [PMID: 16758241 DOI: 10.1007/s00213-006-0368-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
31 Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton HA, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH. Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach. Pharm Res 2014;31:2605-17. [PMID: 24792824 DOI: 10.1007/s11095-014-1358-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
32 Seeman MV. History of the dopamine hypothesis of antipsychotic action. World J Psychiatry 2021;11:355-64. [PMID: 34327128 DOI: 10.5498/wjp.v11.i7.355] [Reference Citation Analysis]
33 Seeman MV. The Pharmacodynamics of Antipsychotic Drugs in Women and Men. Front Psychiatry 2021;12:650904. [PMID: 33897500 DOI: 10.3389/fpsyt.2021.650904] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Veselinović T, Schorn H, Vernaleken I, Schiffl K, Hiemke C, Zernig G, Gur R, Gründer G. Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers. Psychopharmacology (Berl) 2011;218:733-48. [PMID: 21643673 DOI: 10.1007/s00213-011-2368-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
35 Kraguljac NV, McDonald WM, Widge AS, Rodriguez CI, Tohen M, Nemeroff CB. Neuroimaging Biomarkers in Schizophrenia. Am J Psychiatry 2021;178:509-21. [PMID: 33397140 DOI: 10.1176/appi.ajp.2020.20030340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
36 Bryant CA, Jackson SH. Functional imaging of the brain in the evaluation of drug response and its application to the study of aging. Drugs Aging 1998;13:211-22. [PMID: 9789725 DOI: 10.2165/00002512-199813030-00004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
37 De Rossi P, Chiapponi C, Spalletta G. Brain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter Systems. Curr Neuropharmacol 2015;13:435-44. [PMID: 26412063 DOI: 10.2174/1570159x13666150507223542] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
38 Suzuki K, Harada A, Suzuki H, Miyamoto M, Kimura H. TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms. Neuropsychopharmacology 2016;41:2252-62. [PMID: 26849714 DOI: 10.1038/npp.2016.20] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
39 Tateno A, Sakayori T, Kim WC, Honjo K, Nakayama H, Arakawa R, Okubo Y. Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO. Int J Neuropsychopharmacol 2018;21:522-7. [PMID: 29346639 DOI: 10.1093/ijnp/pyy004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
40 Kim E, Howes OD, Veronese M, Beck K, Seo S, Park JW, Lee JS, Lee YS, Kwon JS. Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study. Neuropsychopharmacology 2017;42:941-50. [PMID: 27857125 DOI: 10.1038/npp.2016.258] [Cited by in Crossref: 56] [Cited by in F6Publishing: 36] [Article Influence: 11.2] [Reference Citation Analysis]
41 Stern S, Linker S, Vadodaria KC, Marchetto MC, Gage FH. Prediction of response to drug therapy in psychiatric disorders. Open Biol. 2018;8. [PMID: 29794033 DOI: 10.1098/rsob.180031] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
42 Bossé R, DiPaolo T. The modulation of brain dopamine and GABAA receptors by estradiol: a clue for CNS changes occurring at menopause. Cell Mol Neurobiol 1996;16:199-212. [PMID: 8743969 DOI: 10.1007/BF02088176] [Cited by in Crossref: 48] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
43 de Greef R, Maloney A, Olsson-Gisleskog P, Schoemaker J, Panagides J. Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms. AAPS J 2011;13:121-30. [PMID: 21184291 DOI: 10.1208/s12248-010-9247-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
44 Liperoti R, Pedone C, Corsonello A. Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD). Curr Neuropharmacol 2008;6:117-24. [PMID: 19305792 DOI: 10.2174/157015908784533860] [Cited by in Crossref: 68] [Cited by in F6Publishing: 50] [Article Influence: 6.2] [Reference Citation Analysis]
45 Li YC, Yang SS, Gao WJ. Disruption of Akt signaling decreases dopamine sensitivity in modulation of inhibitory synaptic transmission in rat prefrontal cortex. Neuropharmacology 2016;108:403-14. [PMID: 27163190 DOI: 10.1016/j.neuropharm.2016.05.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
46 Yoon JH, Minzenberg MJ, Raouf S, D'Esposito M, Carter CS. Impaired prefrontal-basal ganglia functional connectivity and substantia nigra hyperactivity in schizophrenia. Biol Psychiatry 2013;74:122-9. [PMID: 23290498 DOI: 10.1016/j.biopsych.2012.11.018] [Cited by in Crossref: 92] [Cited by in F6Publishing: 69] [Article Influence: 11.5] [Reference Citation Analysis]
47 Toda M, Abi-Dargham A. Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep. 2007;9:329-336. [PMID: 17880866 DOI: 10.1007/s11920-007-0041-7] [Cited by in Crossref: 132] [Cited by in F6Publishing: 110] [Article Influence: 9.4] [Reference Citation Analysis]
48 Cocchi E, Drago A, Serretti A. Hippocampal Pruning as a New Theory of Schizophrenia Etiopathogenesis. Mol Neurobiol 2016;53:2065-81. [PMID: 25902861 DOI: 10.1007/s12035-015-9174-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
49 Ľupták M, Michaličková D, Fišar Z, Kitzlerová E, Hroudová J. Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets. World J Psychiatry 2021;11:277-96. [PMID: 34327122 DOI: 10.5498/wjp.v11.i7.277] [Reference Citation Analysis]
50 Nishibe H, Tateno A, Sakayori T, Yamamoto M, Kim W, Kakuyama H, Okubo Y. Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia. Int J Neuropsychopharmacol 2021;24:108-17. [PMID: 32936897 DOI: 10.1093/ijnp/pyaa071] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Smart K, Naganawa M, Baldassarri SR, Nabulsi N, Ropchan J, Najafzadeh S, Gao H, Navarro A, Barth V, Esterlis I, Cosgrove KP, Huang Y, Carson RE, Hillmer AT. PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human Brain. Cereb Cortex 2021;31:2787-98. [PMID: 33442731 DOI: 10.1093/cercor/bhaa387] [Reference Citation Analysis]
52 Stone JM, Davis JM, Leucht S, Pilowsky LS. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull. 2009;35:789-797. [PMID: 18303092 DOI: 10.1093/schbul/sbn009] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
53 Mihali A, Subramani S, Kaunitz G, Rayport S, Gaisler-Salomon I. Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery. Expert Rev Neurother 2012;12:785-99. [PMID: 22853787 DOI: 10.1586/ern.12.60] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
54 Wulff S, Pinborg LH, Svarer C, Jensen LT, Nielsen MØ, Allerup P, Bak N, Rasmussen H, Frandsen E, Rostrup E, Glenthøj BY. Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome. Schizophr Bull 2015;41:1143-52. [PMID: 25698711 DOI: 10.1093/schbul/sbu220] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
55 Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, Ohta K, Kato M, Okubo Y, Suhara T. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 2008;197:229-35. [PMID: 18058087 DOI: 10.1007/s00213-007-1029-z] [Cited by in Crossref: 84] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
56 Manvich DF, Petko AK, Branco RC, Foster SL, Porter-Stransky KA, Stout KA, Newman AH, Miller GW, Paladini CA, Weinshenker D. Selective D2 and D3 receptor antagonists oppositely modulate cocaine responses in mice via distinct postsynaptic mechanisms in nucleus accumbens. Neuropsychopharmacology 2019;44:1445-55. [PMID: 30879021 DOI: 10.1038/s41386-019-0371-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
57 Martinot JL, Paillère-Martinot ML, Poirier MF, Dao-Castellana MH, Loc'h C, Mazière B. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology (Berl) 1996;124:154-8. [PMID: 8935811 DOI: 10.1007/BF02245616] [Cited by in Crossref: 47] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
58 Sekine M, Maeda J, Shimada H, Nogami T, Arakawa R, Takano H, Higuchi M, Ito H, Okubo Y, Suhara T. Central nervous system drug evaluation using positron emission tomography. Clin Psychopharmacol Neurosci 2011;9:9-16. [PMID: 23431048 DOI: 10.9758/cpn.2011.9.1.9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
59 Chue P. Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic. Neuropsychiatr Dis Treat 2007;3:13-39. [PMID: 19300536 DOI: 10.2147/nedt.2007.3.1.13] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
60 Suzuki K, Harada A, Suzuki H, Capuani C, Ugolini A, Corsi M, Kimura H. Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents. Pharmacol Res Perspect 2018;6. [PMID: 29417763 DOI: 10.1002/prp2.372] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
61 Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry. 2014;19:20-29. [PMID: 24166406 DOI: 10.1038/mp.2013.136] [Cited by in Crossref: 139] [Cited by in F6Publishing: 113] [Article Influence: 17.4] [Reference Citation Analysis]
62 Yanai K, Ryu JH, Watanabe T, Iwata R, Ido T, Sawai Y, Ito K, Itoh M. Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br J Pharmacol 1995;116:1649-55. [PMID: 8564232 DOI: 10.1111/j.1476-5381.1995.tb16386.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 55] [Article Influence: 3.2] [Reference Citation Analysis]
63 Apiquian R, Fresán A, de la Fuente-Sandoval C, Ulloa RE, Nicolini H. Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns. BMC Psychiatry 2004;4:12. [PMID: 15109398 DOI: 10.1186/1471-244X-4-12] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
64 Jeon SW, Kim YK. Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome. Int J Mol Sci 2017;18:E2174. [PMID: 29057817 DOI: 10.3390/ijms18102174] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
65 Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs 2011;25:829-45. [PMID: 21936586 DOI: 10.2165/11591690-000000000-00000] [Cited by in Crossref: 6] [Cited by in F6Publishing: 23] [Article Influence: 0.7] [Reference Citation Analysis]
66 Tashiro M, Mochizuki H, Sakurada Y, Ishii K, Oda K, Kimura Y, Sasaki T, Ishiwata K, Yanai K. Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. Br J Clin Pharmacol 2006;61:16-26. [PMID: 16390347 DOI: 10.1111/j.1365-2125.2005.02514.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
67 McQueen G, Lay A, Lally J, Gabay AS, Collier T, Lythgoe DJ, Barker GJ, Stone JM, McGuire P, MacCabe JH, Egerton A. Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia. Psychopharmacology (Berl) 2020;237:443-51. [PMID: 31786651 DOI: 10.1007/s00213-019-05382-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
68 Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull. 2009;35:549-562. [PMID: 19325164 DOI: 10.1093/schbul/sbp006] [Cited by in Crossref: 1458] [Cited by in F6Publishing: 1116] [Article Influence: 121.5] [Reference Citation Analysis]
69 Reinen JM, Van Snellenberg JX, Horga G, Abi-Dargham A, Daw ND, Shohamy D. Motivational Context Modulates Prediction Error Response in Schizophrenia. Schizophr Bull 2016;42:1467-75. [PMID: 27105903 DOI: 10.1093/schbul/sbw045] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
70 Gemperle AY, McAllister KH, Olpe HR. Differential effects of iloperidone, clozapine, and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm. Psychopharmacology (Berl) 2003;169:354-64. [PMID: 12827343 DOI: 10.1007/s00213-003-1459-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]